INmune Bio (INMB) announced new imaging data from its Phase 2 study of XPro in patients with early Alzheimer's disease, to be presented at an Alzheimer's Association meeting. The update is informative but no efficacy/safety figures were provided in the article excerpt, so near-term impact is likely limited.
INmune Bio (INMB) announced new imaging data from its Phase 2 study of XPro in patients with early Alzheimer's disease, to be presented at an Alzheimer's Association meeting. The update is informative but no efficacy/safety figures were provided in the article excerpt, so near-term impact is likely limited.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
